Piperacillin Sod Tazobactam So (Zosyn) — Compare Prices at US & Canada Pharmacies

Piperacillin-tazobactam (brand Zosyn) pairs an extended-spectrum penicillin with tazobactam, a beta-lactamase inhibitor that blocks the enzyme many resistant bacteria use to destroy piperacillin on its own. The combination is one of the most heavily used broad-spectrum IV antibiotics in US hospitals — a workhorse for intra-abdominal infections, hospital-acquired and ventilator-associated pneumonia, complicated skin infections, and empiric coverage for febrile neutropenia or suspected sepsis, largely because it reliably covers Pseudomonas aeruginosa in addition to typical Gram-positive, Gram-negative, and anaerobic organisms — a combination of coverage that fewer single antibiotics offer.

Its most discussed modern safety issue is a well-documented interaction, not with another drug's effect but with kidney injury risk: combining piperacillin-tazobactam with vancomycin is associated with a meaningfully higher rate of acute kidney injury than either drug used with a different partner, a finding from multiple large studies that has changed prescribing habits — many hospitals now favor alternative combinations (such as cefepime plus vancomycin) for empiric double coverage specifically to avoid this synergistic renal risk, or monitor kidney function especially closely when the combination can't be avoided.

Two other practical points: piperacillin-tazobactam carries a meaningful sodium load per dose, which matters for patients with heart failure or significant kidney disease on fluid restriction, and it can cause a false-positive result on the galactomannan test used to screen for invasive aspergillosis in immunocompromised patients — a lab-interference issue worth knowing if a patient on this drug is also being worked up for a fungal infection. As a broad-spectrum penicillin combination, it sits in WHO's Watch AWaRe category, and hospitals track its use as part of antibiotic stewardship.